XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 12 - Revenue From Product Sales | 3 Months Ended
--- | ---
Mar. 31, 2026
Notes to Financial Statements |
Revenue from Contract with Customer [Text Block] | Note 12 – Revenue From Product Sales Net product sales consist of the following for the three months ended March 31, 2026 and 2025 (in thousands):
|  | Three Months Ended |
|  | March 31, |
|  | 2026 |  |  | 2025 |
Jelmyto |  | $ | 21,713 |  |  | $ | 20,254 |
Zusduri |  |  | 29,246 |  |  |  | — |
Total Revenue |  | $ | 50,959 |  |  | $ | 20,254 |
All product sales of Jelmyto and Zusduri are recognized through the Company's arrangements with two customers as defined by ASC 606, both of which are third-party national specialty distributors. The Company's largest customer comprised approximately 58% of product sales for the three months ended March 31, 2026, and over 85% of product sales for the three months ended March 31, 2025. The Company's largest customer comprised approximately 48% and 59% of accounts receivable at March 31, 2026 and December 31, 2025, respectively. Net revenue recognized includes gross revenue and management’s estimate of returns, consideration paid to the customers, such as rebates, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340B drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company’s copay assistance program, and Medicare refunds for discarded drug. The Company does not anticipate any Medicare refunds for discarded drug for Zusduri. The Company estimates these elements of variable consideration based on the contractual or statutory terms governing the arrangements and the Company’s historical experience, and constrains the net revenue recognized for product sales to the value that is not probable to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. Reserves for chargebacks and returns are net settled and recognized as contra accounts receivable while the remaining reserves are recognized within other current liabilities on the condensed consolidated balance sheets. The following table shows the activity with respect to sales reserves for the period ended March 31, 2026 and 2025 (in thousands):
|  | Reserves related to government sponsored programs |  |  | Medicare refunds for discarded drug reserve |  |  | Other reserves |  |  | Total accrued sales reserves |
Balance as of December 31, 2025 |  | $ | 1,530 |  |  | $ | 4,022 |  |  | $ | 3,849 |  |  | $ | 9,401 |
Accruals |  |  | 5,605 |  |  |  | 884 |  |  |  | 6,545 |  |  |  | 13,034 |
Utilizations |  |  | (5,566 | ) |  |  | — |  |  |  | (4,966 | ) |  |  | (10,532 | )
Balance as of March 31, 2026 |  | $ | 1,569 |  |  | $ | 4,906 |  |  | $ | 5,428 |  |  | $ | 11,903 |
Balance as of December 31, 2024 |  | $ | 887 |  |  | $ | 7,729 |  |  | $ | 1,946 |  |  | $ | 10,562 |
Accruals |  |  | 3,686 |  |  |  | 903 |  |  |  | 2,713 |  |  |  | 7,302 |
Utilizations |  |  | (3,889 | ) |  |  | (3,809 | ) |  |  | (2,926 | ) |  |  | (10,624 | )
Balance as of March 31, 2025 |  | $ | 684 |  |  | $ | 4,823 |  |  | $ | 1,733 |  |  | $ | 7,240 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration